B+L launches PureVision2 Multi-Focal

Article

Bausch + Lomb introduced PureVision2 Multi-Focal (balafilcon A) monthly silicone hydrogel multifocal contact lenses at the American Academy of Optometry meeting. Featuring a next-generation 3-zone progressive design, these lenses are designed to improve near and intermediate vision while providing excellent distance clarity.

 

Seattle-Bausch + Lomb introduced PureVision2 Multi-Focal (balafilcon A) monthly silicone hydrogel multifocal contact lenses at the American Academy of Optometry meeting. Featuring a next-generation 3-zone progressive design, these lenses are designed to improve near and intermediate vision while providing excellent distance clarity.

The lens design allows for a more predictable, quick fit for the eyecare professional. According to the company, PureVision2 Multi-Focal helped maintain clear near, intermediate, and distance vision in real-world conditions.

The lenses are approved for extended wear up to 30 days in powers ranging from +6.00 D to –10.00 D in 0.25 D steps. Low add power helps patients needing 0.75 D to 1.50 D of near power, while the high add power addresses needs of 1.75 D to 2.50 D. Base curve is 8.6 mm, and diameter is 14.0 mm.

“We know that consistent, crisp, clear vision at all distances can be a challenge for people with presbyopia. These new lenses will provide that consistency whether viewing a screen on your mobile phone or a screen at the cinema,” said Joseph Barr, OD, MS, vice president, Medical Affairs, Pharmaceuticals, Vision Care, Bausch + Lomb. “We’re optimistic that the combination of a streamlined fit and a satisfied patient will make this lens a favorite for the eyecare professional.”

 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
© 2025 MJH Life Sciences

All rights reserved.